Immunic (NASDAQ:IMUX) posted its quarterly earnings data on Thursday. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.80), Bloomberg Earnings reports.
Shares of NASDAQ:IMUX traded up $0.20 on Friday, hitting $13.01. 23,600 shares of the company were exchanged, compared to its average volume of 167,669. Immunic has a one year low of $6.00 and a one year high of $390.00. The company has a market cap of $14.30 million, a price-to-earnings ratio of -0.37 and a beta of 3.68.
IMUX has been the topic of several research reports. Chardan Capital initiated coverage on shares of Immunic in a report on Thursday, July 11th. They set a “buy” rating and a $40.00 price objective on the stock. ValuEngine upgraded shares of Immunic from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Further Reading: What are the disadvantages of after-hours trading?
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.